UNSPSC 51314364: Dextromethorphan/guaifenesin/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314364 Dextromethorphan/guaifenesin/pseudoephedrine is a Commodity code that in practice covers pharmaceutical procurement by state and local health agencies, including naloxone, OTC cough and cold remedies, and generic multi-source pharmaceuticals for distribution through public health systems and cooperative purchasing programs. Recent solicitations show state health departments and county health agencies purchasing finished pharmaceutical products—both brand and generic formulations—for community health initiatives, emergency response, and employee/retiree pharmacy benefit programs. The Texas Health and Human Services Commission, Minnesota Department of Administration, and Seminole County, Florida have all posted opportunities under or closely aligned with this code in the past four months, signaling active procurement across state health systems, cooperative purchasing alliances, and county public health infrastructure.

Recent activity concentrates in Texas, Minnesota, and Florida. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP on January 20, 2026 (due March 26, 2026) seeking manufacturers to supply generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026 and contract terms through June 30, 2028. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, on a fixed-fee basis with a two-year initial term and one-year renewal option. The Texas HHS Commission released an RFI on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, designed as preliminary market intelligence before a formal RFP. Vendors responding to these opportunities must comply with cGMP and DSCSA requirements, maintain relationships with authorized wholesalers, meet insurance thresholds of $2 million to $5 million in coverage, and demonstrate E-Verify compliance and drug-free workplace certification.